2023
DOI: 10.1111/joim.13697
|View full text |Cite
|
Sign up to set email alerts
|

Novel precision medicine approaches and treatment strategies in hematological malignancies

Abstract: Genetic testing has been applied for decades in clinical routine diagnostics of hematological malignancies to improve disease (sub)classification, prognostication, patient management, and survival. In recent classifications of hematological malignancies, disease subtypes are defined by key recurrent genetic alterations detected by conventional methods (i.e., cytogenetics, fluorescence in situ hybridization, and targeted sequencing). Hematological malignancies were also one of the first disease areas in which t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 11 publications
(2 citation statements)
references
References 199 publications
0
2
0
Order By: Relevance
“…Chemotherapy, radiotherapy, targeted drug therapy, immunotherapy, and HSCT are the current therapeutic strategies for hematological malignancies. 309 However, each therapy is only effective for some malignant hematological diseases and some patients fail due to relapse and drug resistance, therefore, precision medicine and individualized treatment for patients with hematological malignancies are still the focus of research. 310 …”
Section: Gene Therapy In Human Diseasesmentioning
confidence: 99%
“…Chemotherapy, radiotherapy, targeted drug therapy, immunotherapy, and HSCT are the current therapeutic strategies for hematological malignancies. 309 However, each therapy is only effective for some malignant hematological diseases and some patients fail due to relapse and drug resistance, therefore, precision medicine and individualized treatment for patients with hematological malignancies are still the focus of research. 310 …”
Section: Gene Therapy In Human Diseasesmentioning
confidence: 99%
“…There has arguably never been a more exciting time to be a clinician or researcher within the field of Oncology/Transplant Infectious Diseases than the present. Progress in the genetic characterization of hematologic malignancies has driven advancements in diagnostic, prognostics, and therapeutics, leading to a rapidly growing repertoire of targeted treatments 1 . Significant developments in hematopoietic cell transplantation (HCT) have increased eligibility for both candidates and donors, leading to more than 80,000 HCTs performed annually worldwide 2,3 .…”
mentioning
confidence: 99%